AI
VNDA icon

Axiom Investors’s Vanda Pharmaceuticals VNDA Stock Holding History

Axiom Investors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-137,167
Closed -$2.46M – 157
2017
Q3 		$2.46M Buy
137,167
+2,514
+2% +$42.1K 0.06% 113
2017
Q2 		$2.19M Buy
134,653
+5,297
+4% +$76.3K 0.05% 119
2017
Q1 		$1.81M Sell
129,356
-18,420
-12% -$263K 0.05% 128
2016
Q4 		$2.36M Buy
+147,776
New +$2.38M 0.07% 118

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Axiom Investors's VNDA Position: Q4 2017 in Review

Axiom Investors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2017, closing a stake of 137,167 shares — an estimated $2.46M sold.

Axiom Investors first reported a position in VNDA in Q4 2016 and held it in 4 quarters. The position peaked at $2.46M in Q3 2017. 125 funds tracked by Wall St. Rank hold VNDA as of Q4 2017.

  • Axiom Investors reported no remaining Vanda Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Axiom Investors sold 137,167 Vanda Pharmaceuticals shares in Q4 2017, an estimated $2.46M.
  • Axiom Investors first reported a position in Vanda Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Axiom Investors's Vanda Pharmaceuticals position peaked at $2.46M in Q3 2017.
  • 125 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2017.

Based on Axiom Investors's 13F filing for Q4 2017, filed 14 Feb 2018.